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Abstract
Background: The project "Antibiotic resistance in bacteria of animal origin – II" (ARBAO-II) was
funded by the European Union (FAIR5-QLK2-2002-01146) for the period 2003–05. The aim of this
project was to establish a program for the continuous monitoring of antimicrobial susceptibility of
pathogenic and indicator bacteria from food animals using validated and harmonised
methodologies. In this report the first data on the occurrence of antimicrobial resistance among
bacteria causing infections in pigs are reported.
Methods: Susceptibility data from 17,642 isolates of pathogens and indicator bacteria including
Actinobacillus pleuropneumoniae, Streptococcus suis and Escherichia coli isolated from pigs were
collected from fifteen European countries in 2002–2004.
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Acta Veterinaria Scandinavica 2008, 50:19 http://www.actavetscand.com/content/50/1/19Results: Data for A. pleuropneumoniae from infected pigs were submitted from five countries. Most
of the isolates from Denmark were susceptible to all drugs tested with the exceptions of a low
frequency of resistance to tetracycline and trimethoprim – sulphonamide.
Data for S. suis were obtained from six countries. In general, a high level of resistance to
tetracycline (48.0 – 92.0%) and erythromycin (29.1 – 75.0%) was observed in all countries whereas
the level of resistance to ciprofloxacin and penicillin differed between the reporting countries.
Isolates from England (and Wales), France and The Netherlands were all susceptible to penicillin.
In contrast the proportion of strains resistant to ciprofloxacin ranged from 12.6 to 79.0% (2004)
and to penicillin from 8.1 – 13.0% (2004) in Poland and Portugal.
Data for E. coli from infected and healthy pigs were obtained from eleven countries.  The data reveal
a high level of resistance to tetracyclines, streptomycin and ampicillin among infected pigs whereas
in healthy pigs the frequency of resistance was lower.
Conclusion: Bacterial resistance to some antimicrobials was frequent with different levels of
resistance being observed to several antimicrobial agents in different countries. The occurrence of
resistance varied distinctly between isolates from healthy and diseased pigs, with the isolates from
healthy pigs generally showing a lower level of resistance than those from diseased pigs.
The study suggests that the choice of antimicrobials used for the treatment of diseased animals 
should preferably be based on knowledge of the local pattern of resistance.
Background
Antimicrobial agents are important drugs for the treat-
ment of bacterial infections in pigs. Because of intensive
pig rearing in Europe, large numbers of pigs are treated
annually. However, the specific bacterial aetiology and
the antimicrobial susceptibility of the bacteria are only
determined in a limited number of cases irrespectively of
country. During acute infections it is important to use an
effective antimicrobial treatment as early as possible.
Often treatment is initiated before or even without subse-
quent bacteriological examination of diseased pigs. For
some bacterial species the susceptibility data are available,
whereas for other species, the susceptibility pattern varies
or is unknown. Therefore the empirical treatment has to
be based mostly on a general knowledge regarding the
successful usage of certain drugs on the farm in question.
The introduction of indicator organisms in baseline mon-
itoring studies has resulted in knowledge on existing
resistance genes reservoirs, which potentially can be trans-
ferred to pathogenic bacteria. The resistance among indi-
cator bacteria reflects a certain selective pressure caused by
the general use of antimicrobials in animal production
and the adaptation of these bacteria to the new condi-
tions. That means on a global view that there is a selection
of the fittest microorganisms based on the presence of
resistance determinants and their stable inheritance.
There are only a few internationally reported studies on
the occurrence of antimicrobial resistance in bacteria
causing infections in food animals in Europe.
To compensate for this, the ARBAO-II-project was funded
by the European Union (FAIR5-QLK2-2002-01146). This
study was funded for the period 2003–05 with the aim to
establish a continuous monitoring of antimicrobial sus-
ceptibility of pathogenic and indicator bacteria isolated
from food animals at 19 veterinary laboratories in 18
European countries. Most of the laboratories use validated
and harmonised methodologies. In this report the first
data on the occurrence of antimicrobial resistance among
bacteria causing infections in pigs are reported.
Methods
Participating laboratories
Each year the laboratories participating in the project were
requested to fill in excel-file templates with national sum-
mary data on the occurrence of antimicrobial resistance
from different bacterial species and groups. The partici-
pants were asked to submit national data but if this was
not possible they were advised to submit regional or insti-
tutional data as done by England, including Wales. The
data for some countries were incomplete e.g. for Austria
and Latvia and data was deducted for others if the number
of isolates were lower than 31.
Quality control
Invitation was announced annually through the network
by email or facsimile to all ARBAO members to participate
in self-evaluating proficiency tests (EQAS external quality
assurance system) for antimicrobial susceptibility testing.
The tests were conducted each year to test if the current
methodologies were accurate, adequate and reliable [1,2].
In addition, the EQAS served as a tool to pin out the lab-Page 2 of 10
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was to have all laboratories to perform antimicrobial sus-
ceptibility testing with a maximum of 10% total devia-
tions (minor, major, or very major deviations) and a
maximum of 5% critical deviations (major or very major
deviations).
Eight strains of each of the species Staphylococcus aureus,
Mannheimia haemolytica, Pasteurella multocida, Streptococ-
cus dysgalactiae, Streptococcus uberis and Escherichia coli
were selected for each EQAS iteration. Strains were
obtained from the bacterial strain collection at the
National Food Institute, Technical University of Den-
mark. All strains were included in only one EQAS itera-
tion. The strains were inoculated to agar stab cultures for
shipping to the participating laboratories. Participating
laboratories also received a lyophilised reference strain as
a quality control strain for susceptibility testing (E. coli
ATCC 25922; Campylobacter jejuni ATCC 33560; Enterococ-
cus faecalis ATCC 29212, S. aureus ATCC 25923, and S.
aureus ATCC 29213) in each EQAS shipment.
The laboratories were instructed to follow specified testing
instructions; subculture the test strains and propagates the
quality control strains prior to performing the susceptibil-
ity method routinely used by the laboratory. In addition,
laboratories were advised to maintain the quality control
strain for future proficiency tests. After completion of the
susceptibility testing of the test strains and the quality
control strain, the participating laboratories were
instructed to record the obtained results using MIC values
or zone-diameter in millimetres and categorize each of the
tested strains as either "resistant" (R), "intermediate" (I)
or "susceptible" (S) against each tested antimicrobial
agent using the breakpoints routinely used in their labora-
tory. They were then asked to record the information on
the participating laboratory record sheet.
After submitting results, participating laboratories
received an individual report. The individual reports for
the participating laboratories reported all deviations from
the expected values and suggestions of how to either solve
or investigate the problem. For the quality control strains,
deviations were defined as values that exceeded the qual-
ity control range of the strain. Deviations of the antimicro-
bial susceptibility results were categorised as minor, major
or very major. A minor deviation was defined as an inter-
mediate strain that was classified as susceptible or resist-
ant or vice versa (i.e. I ↔ S or I ↔ R). A major deviation
was defined as a susceptible strain that was classified as
resistant (i.e. S → R). A very major deviation was defined
as a resistant strain that was classified as susceptible (i.e. R
→ S).
The overall performance and the results were between 85–
100% correct. In general, the concordance between results
for Gram-negative bacteria was good e.g. 93% in 2003
and 95% in 2004 for E. coli. Therefore the summary results
for these species might be compared between countries
generally.
Test methods
Each laboratory reported annually, which methods were
used for antimicrobial susceptibility testing. Laboratories
in Austria, England (including Wales), France, Italy, Latvia
and Poland used disc diffusion test, whereas Denmark,
The Netherlands, Norway, Sweden and Switzerland used
the broth micro dilution method by which minimal inhi-
bition concentration (MIC) are determined. Spain and
Finland used both MIC determination and disc diffusion,
whereas Belgium used tablet diffusion. Portugal utilized a
micro-broth dilution test – the automated ATB suscepti-
bility test strip http://www.biomerieux-diagnostics.com.
The manufactures of discs and microtitre plates for broth
microdilution differed between countries.
All countries reported the extent to which they followed
the standards of the Clinical and Laboratory Standards
Institute (CLSI), M31-A2, M7-A6 or M2-A8 [3]. Austria,
England (including Wales), France, The Netherlands, Nor-
way, Sweden and Switzerland reported that they did not
use CLSI breakpoints as listed in the fifteenth interna-
tional supplement M100-S15 to determine the antimicro-
bial susceptibility levels but a mixture of these and
national established breakpoints. Despite the differences
in used breakpoints all of the countries performed suscep-
tibility testing within the EQAS QC threshold.
Results
Susceptibility data were obtained from 17,642 bacterial
isolates from 15 European countries over the three year
period 2002–2004 (Table 1). The national data on suscep-
tibility testing of each species varied considerably, i.e. 24
isolates of S. suis were tested in Portugal while 1,442 iso-
lates of infectious E. coli were tested in France. The bacte-
rial species and their antimicrobial resistance are given in
Tables 1, 2, 3, 4, 5.
Actinobacillus pleuropneumoniae
Susceptibility data for A. pleuropneumoniae from infected
pigs were obtained from five countries, which annually
tested between 583 and 938 isolates (Tables 1 and 2). In
general, nearly all of the isolates from Denmark showed
low resistance to all drugs tested. In England (and Wales),
resistance was observed which seemed to decrease over
time for ampicillin (4.0% in 2002 to 2.0% in 2004) and
ciprofloxacin (from 4.0%, in 2002 to 0.0% in 2004).Page 3 of 10
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Table 1: Data on antimicrobial susceptibility submitted from the participating laboratories in the different European countries during 
a three year period.
Bacterial 
species
A. pleuropneumoniae S. suis E. coli (Infections) E. coli (Indicator) Total
Year 2002 2003 2004 2002 2003 2004 2002 2003 2004 2002 2003 2004 2002 2003 2004
Country 
and 
number of 
bacterial 
isolates
A - - - - - - - - - - - 217 - - 217
B - - - - - - 61 100 137 146 - - 207 100 137
DK 480 514 441 - 557 - 111 77 177 293 317 208 884 1,465 826
Eb 54 46 43 - 34 53 365 352 313 - - - 419 432 409
Fa 118–157 1271–88 99–130 92–210 68–305 72–196 862–1,442 784–1,364 758–1 412 101 101 100 1,055–1,753 1,080–1,958 1,029–1,838
FIN - - - - - - 141 65 61 - - 391 141 65 452
I - - - - - - - - - - 103 166 - 103 166
LV - - - - - - - 31 - - - - - 31 -
NL - 190 - - 762 - 311 308 - 149 155 296 460 1,415 296
N - - - - - - 39 - 45 187 - 125 226 - 170
PL 32 - - 150 151 111 - - - - - 355 182 151 466
P - - - - - 24 33 45 44 - - - 33 45 68
ES - - - - - - 77 154 169 289 285 183 366 439 352
S - - - - - - 340 45 386 - 303 - - 348 386
CH - - - - - - - 92 47 - - - - 92 47
Total no. 
of isolates
685–723 877–938 583–614 242–360 1,572–1,809 260–384 2,340–2,920 2,053–2,633 2,137–2,791 1,17 1,26 2,04
-: No data available, a Multicenter study. The isolates were tested for different panels of antimicrobial agents in the different centers. b: Isolates from England included also Wales and have been collected by The Veterinary Laboratory Agency. The 
remaining part of the United Kingdom has separate laboratories.
A – Austria; B – Belgium, DK – Denmark, E – England including Wales; F – France; FIN – Finland; I – Italy; LV – Latvia; NL – The Netherlands; N – Norway; PL – Poland; P – Portugal; ES – Spain; S – Sweden; CH – Switzerland
Table 2: Occurrence of antimicrobial resistance among Actinobacillus pleuropneumoniae isolated from pigs in different European 
countries.
Antimicrobial agent Year Country and prevalence of resistance
DK E F NL PL
Ampicillin 2002 0.0 4.0 1.3 - 2.0
2003 0.2 7.0 0.5 8.0 -
2004 0.0 2.0 0.8 - -
Amoxicillin – Clavulanic acid 2002 - - 0.0 - 0.0
2003 - - 0.0 0.0 -
2004 - - 0.0 - -
Ciprofloxacin 2002 0.0 4.0 0.0 - 1.0
2003 0.0 0.0 0.0 - -
2004 1.5 0.0 0.0 - -
Florfenicol 2002 - - 0.0 - -
2003 0.0 - 0.0 - -
2004 0.0 - 0.0 - -
Tetracycline 2002 16.0 22.0 11.0 - 4.0
2003 3.7 37.0 10.6 5.0 -
2004 5.7 28.0 4.7 - -
Trimethoprim – Sulphonamide 2002 0.0 13.0 8.3 - 8.0
2003 0.0 46.0 8.0 1.0 -
2004 1.6 28.0 4.6 - -
-: No data available. DK – Denmark, E – England including Wales; F – France; NL – The Netherlands; PL – Poland.
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Over the three-year period, 2,553 isolates were tested with
the majority of these (1,809) isolated in 2003.
In general, a high level of resistance to tetracycline (48.0 –
92.0%), trimethoprim – sulphonamide (3.0 to 51.5%)
and erythromycin (29.1 – 75.0%) was observed in all par-
ticipating countries. However, the number of isolates
being resistant to penicillin differed between the coun-
tries. The isolates from England (and Wales), France and
The Netherlands were susceptible to penicillin. In con-
trast, the resistance level for penicillin in Denmark,
Poland and Portugal ranged from 0.9 to 13.0%.
Resistance to gentamicin was observed only in isolates
from Poland and Portugal. All isolates from Portugal were
completely resistant in 2004. There was a decrease in
resistance to trimethoprim – sulphonamide in France
(from 22.4% in 2002 to 13.3% in 2004) and Poland
(from 30.0% in 2002 to 14.4% in 2004). The frequency of
resistance to trimethoprim – sulphonamide in England
(and Wales) (from 3.0% to 8.0%) and in The Netherlands
(8.0%) were at the same level as in France and Poland in
2004. In contrast, the frequency of resistance to the same
antimicrobial were considerable higher in Denmark
(51.5%) compared to the other countries. Resistance to
penicillin was detected in both Poland (8.1% in 2004)
and Portugal.
Escherichia coli
Susceptibility data for E. coli isolated from diseased pigs
were obtained from 12 countries (Table 4). The 12 coun-
tries submitted susceptibility data for 2,053 – 2,920 iso-
lates annually (Table 1).
In contrast to the other pathogens included in this study,
a frequent occurrence of resistance was observed to several
antimicrobial agents in several countries. However, the
occurrence varied markedly between antimicrobials and
countries but seemed to be very stable within countries
over the three-year period.
A high level of resistance was observed for E. coli to tetra-
cyclines (Sweden: 23.0% in 2003; Portugal: 98.0% in
2004), streptomycin (Sweden: 28.0% in 2004; Latvia:
92.0% in 2004), and ampicillin (Spain: 72.2% in 2004;
The Netherlands: 93.0% in 2003). The isolates were sus-
ceptible or showed relatively low levels of resistance to
ceftiofur (1.0% to 3.6% in Spain). In addition, resistance
to florfenicol showed similar trends as ceftiofur varying
from 4.0% to 7.1% in Spain 2003 – 2004.
Susceptibility data for E. coli isolated from the gastro-
intestinal tract of healthy pigs (indicator bacteria) were
obtained from 11 countries (Table 5). The 11 countries
tested between 1,165 – 2,041 isolates during the three
years period.
Table 3: Occurrence of antimicrobial resistance among Streptococcus suis isolated from pigs in different European countries.
Antimicrobial agent Year Country and prevalence of resistance
DK E F NL PL P
Erythromycin 2002 - - 64.6 - - -
2003 29.1 36.0 52.9 35.0 - -
2004 - 50.0 58.1 - 30.6 75.0
Gentamicin 2002 - - 0.0 - 28.0 -
2003 - - 0.0 - 0.0 -
2004 - - 0.0 - 53.2 100.0
Penicillin 2002 - - 0.0 - 10.6 -
2003 0.9 0.0 0.0 0.0 7.9 -
2004 - 0.0 0.0 - 8.1 13.0
Tetracycline 2002 - - 57.8a - 73.3 -
2003 52.2 68.0 56.7a 48.0 55.0 -
2004 - 68.0 62.5a - 64.0 92.0
Trimethoprim – Sulphonamide 2002 - - 22.4 - 30.0 -
2003 51.5 3.0 15.5 8.0 16.6 -
2004 - 8.0 13.3 - 14.4 -
-: No data available, a: Doxycycline. DK – Denmark, E – England including Wales; F – France; NL – The Netherlands; PL – Poland; P – Portugal.Page 5 of 10
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Antimicrobial agent Year Country and prevalence of resistance
B DK E FIN F LV NL N P ES S CH
Ampicillin 2002 55.7 45.0 43.0 13.0 49.9 - 92.9 13.0 - 77.0 19.0 -
2003 69.2 42.9 51.0 15.4 51.5 65.0 93.0 - - 70.1 14.0 21.0
2004 72.3 45.8 47.0 16.0 53.2 - - 7.0 - 72.2 22.0 4.2
Amoxicillin – Clavulanic acid 2002 11.5 - - - 2.7 - 0.1 - 58.0 1.0 - -
2003 4.4 3.9 - - 9.2 24.0 1.0 - 31.0 2.6 - 0.0
2004 0.7 0.6 - - 2.0 - - - 36.0 1.8 - 0.0
Apramycin 2002 6.6 17.0 12.0 - 3.0 - - 3.0 - 23.0 - -
2003 13.2 9.1 16.0 - 3.7 - - - - 20.8 - -
2004 13.1 13.6 8.0 - 3.3 - - - - 13.0 - -
Ceftiofur 2002 1.6 0.0 - - 0.1 - - 0.0 - 1.0 0.0 -
2003 2.2 0.0 - 0.0 0.0 - - - - - 0.0 0.0
2004 0.7 0.0 - 0.0 0.6 - - 0.0 - 3.6 <1.0 -
Chloramphenicol 2002 49.2 31.0 - - - - - 0.0 42.0 45.0 - -
2003 34.1 25.0 - 3.1 - - - - 49.0 35.1 - 18.7
2004 38.7 41.8 - 7.0 - - - 4.0 45.0 40.8 - 38.3
Ciprofloxacin 2002 3.3 0.0 8.0 4.0 4.7 - - 0.0 76.0a 15.0 7.0 -
2003 1.1 0.0 2.0 1.5 6.2 22.0 - - 38.0a 14.9 0.0 1.3
2004 2.9 0.0 2.0 0.0 5.5 - - 0.0 30.0a 14.2 6.0 0.0
Florfenicol 2002 1.6 0.0 - - 2.0 - - 0.0 - 4.0 0.6 -
2003 2.2 1.3 - 1.5 1.2 - - - - 7.1 0.0 -
2004 4.4 0.0 - 0.0 0.9 - - 0.0 - 7.1 - -
Gentamicin 2002 4.9 14.0 - - 5.6 - 0.0 3.0 58.0 25.0 1.0 -
2003 1.1 6.5 - 0.0 6.1 15.0 - - 33.0 19.5 2.0 15.8
2004 3.6 12.0 - 0.0 5.5 - - 0.0 45.0 19.5 0.0 12.7
Nalidixic acid 2002 19.7 19.0 - - 17.1 - 0.0 0.0 85.0b 45.0 - -
2003 18.7 25.3 - 21.5 - 35.0 <1.0 - - 42.2 - -
2004 34.3 32.0 - 13.0 - - - 2.0 - 33.7 - -
Neomycin 2002 14.8 36.0 11.0 - 10.6 - 0.0 0.0 - 26.0 4.0 -
2003 2.2 31.2 19.0 3.1 11.8 48.0 0.0 - - 24.7 6.0 12.2
2004 1.5 35.0 11.0 7.0 10.9 - - 2.0 - 20.1 4.0 -
Streptomycin 2002 - 77.0 - 45.0 - - - 54.0 79.0 73.0 33.0 -
2003 - 66.3 - 47.7 - 92.0 - - 60.0 73.4 32.0 -
2004 - 77.4 - 54.0 - - - 47.0 64.0 74.0 28.0 -
Sulphonamide 2002 - 77.0 - - - - - 23.0 - 82.0 - -
2003 - 72.7 - 33.8 - 92.0 - - - 74.7 - -
2004 - 82.0 - 51.0 - - - 7.0 - 76.3 - -
Tetracycline 2002 75.4 75.0 85.0 44.0 86.2 - - 41.0 94.0 86.0 28.0 -
2003 80.2 72.7 83.0 46.2 84.7 86.0 - - 91.0 86.4 23.0 57.8
2004 77.4 91.0 82.0 51.0 82.6 - - 24.0 98.0 87.0 27.0 57.4
Trimethoprim 2002 - - - - - - - 15.0 - 63.0 - -
2003 - - - 29.2 - - - - - 72.1 - -
2004 - - - 44.0 - - - 7.0 - 66.9 27.0 -Page 6 of 10
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compared to pathogenic strains. However, as with the
pathogenic strains, the level of resistance appeared to
increase for some antimicrobials (streptomycin, sul-
phonamides, tetracycline, trimethoprim and trimetho-
prim – sulphonamide). Generally, the frequencies of
resistance were higher in Belgium, Denmark, France, Italy,
The Netherlands and Spain than in the other countries.
Discussion
For each bacterial species a list of relevant antimicrobials
was agreed upon but most laboratories provided data for
different panels of antimicrobial agents. The same hetero-
geneity was observed in the breakpoints applied. We are
aware that publishing data from multiple laboratories can
be very difficult because there might be variations in
methods used, interpretative criteria, etc. In the ideal
world all laboratories would use the same methods and
we could believe that data were directly comparable.
However, since this unfortunately is not the case and there
actually are major differences in the methods used we
decided to ensure the comparability of the data by an
external quality control system and only include data
from laboratories and pathogens where the cut-off was
met. This demonstrates an important problem in per-
forming international monitoring based on data pro-
duced by routine diagnostic work using different panels,
methods, equipment etc. [4,5]. In addition, it shows a
potential for future improvement of international moni-
toring based on comparable data as required by the Zoon-
oses Directive 2003/99/EC [6]. There is currently no
mandatory international standard for antimicrobial test-
ing at diagnostic laboratories in Europe or world-wide
[4,5].
The design used in this study has certain limitations due
to the lack of standardisation of the sample selection and
microbiological procedures used for isolation, but we
believe that this heterogeneity had only a minor effect on
the results. The summary data originate from samples
submitted to diagnostic laboratories in the different coun-
tries. It is believed, that well-standardised and interna-
tional recognised methods have been used as the
laboratories all are appointed as national reference labo-
ratories. The laboratories have categorized the samples
mainly as "diagnostic samples originating from cases of
infection". The S. suis and A. pleuropneumoniae isolates
described in this study were mainly associated with pleu-
ritis whereas E. coli (clinical isolates) were mostly associ-
ated with diarrhoea.
To gain reliable and comparable susceptibility data, an
EQAS program was conducted annually for all organisms
described in the ARBAO II project including S. suis, A.
pleuropneumoniae and E. coli. The results show that despite
the lack of harmonization and standardization of the sus-
ceptibility tests used in the different diagnostic laborato-
ries, the results of the interpret test results were
comparable as to define the sensitivity category.
Actinobacillus pleuropneumoniae
A rise in frequencies of resistance especially to ampicillin,
fluoroquinolones and tetracyclines have been reported
from other countries previously [7-10]. Especially the
reports from Taiwan and Korea indicate a national devel-
opment of A. pleuropneumoniae resistant to multiple anti-
microbials such as ampicillin, chloramphenicol,
flumequine, nalidixic acid, streptomycin, sulphonamide
– trimethoprim and tetracycline [7,9].
The data from our survey may be used as guideline for
empiric treatment in countries with no or low prevalence
of resistance but in the future, the use of antimicrobials
should be based on resistance data obtained from clinical
cases.
Penicillin and tetracyclines have been reported as the
most frequently used drugs for treatment of porcine respi-
ratory tract infections [11,12]. With the frequent occur-
rence of tetracycline resistance, this drug should probably
not be used as a first choice unless susceptibility test
results have shown susceptibility. In countries with no or
low level of resistance to penicillin this drug should be
considered as the first choice for treatment of infections
with A. pleuropneumoniae.
Another possibility is the use of ciprofloxacin although
resistance has also emerged for this class of drugs in some
Trimethoprim – Sulphonamide 2002 67.2 38.0 52.0 38.0 65.1 - 73.7 - - - 21.0 -
2003 70.3 36.4 - - 66.9 79.0 21.5 - - - - 21.5
2004 70.8 48.6 55.0 - 66.4 - - - - - - -
-: No data available, a: enrofloxacin used, b: flumequine used. B – Belgium, DK – Denmark, E – England including Wales; F – France; FIN – Finland; LV 
– Latvia; NL – The Netherlands; N – Norway; P – Portugal; ES – Spain; S – Sweden; CH – Switzerland.
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Antimicrobial agent Year Country and prevalence of resistance
A B DK FIN F I NL N PL ES S
Ampicillin 2002 - 62 10.9 - 31.0 - 25.5 5.9 - 56.7 -
2003 - - 22.7 - 26.5 46.0 27.7 a - - 68.4 3.0
2004 6.0 - 33.2 6.0 22.0 54.2 25.3 8.0 9.5 69.9 -
Amoxicillin + Clavulanic acid 2002 - 1 - - - - - - - 2.4 -
2003 - - 0.3 - - 1.0 - - - 0.7 0.3
2004 0.0 - 1.0 - - 1.2 - - - 0.0 -
Apramycin 2002 - 4 0.3 - 2.0 - - 0.0 - 5.9 -
2003 - - 0.9 - 9.1 - - - - 4.2 0.0
2004 1.8 - 3.4 - 4.0 - - - - 4.9 -
Ceftiofur 2002 - 1 0.0 - - - 0.0 0.0 - 0.0 -
2003 - - 0.0 - - 0.0 0.6 a - - 0.0 0.0
2004 0.0 - 0.0 0.0 - 0.0 0.3 0.0 0.6 0.5 -
Chloramphenicol 2002 - 33 3.7 - 21.0 - 9.4 0.5 - 30.5 -
2003 - - 6.7 - 21.4 26.0 7.7 a - - 37.9 0.7
2004 3.7 - 9.1 1.0 14.0 28.9 12.2 0.8 2.5 30.6 -
Ciprofloxacin 2002 - 2 0.0 - 0.0 - 0.0 0.0 - 1.7 -
2003 - - 1.8 - 0.0 1.0 0.0a - - 1.1 1.0
2004 0.9 - 0.0 0.0 1.0 5.4 0.0 0.0 2.5 3.3 -
Florfenicol 2002 - 1 0.0 - 1.0 - 0.0 0.0 - 0.7 -
2003 - - 0.0 - 2.0 - 0.6a - - 2.1 0.0
2004 0.0 - 0.0 0.0 1.0 - 0.0 0.0 2.0 2.2 -
Gentamicin 2002 - 3 0.3 - 0.0 - 1.3 0.0 - 4.8 -
2003 - - 0.6 - 3.1 2.0 1.3a - - 5.3 0.0
2004 0.9 - 3.4 0.0 0.0 1.2 0.3 0.0 0.6 7.7 -
Nalidixic acid 2002 - 5 1.0 - 5.0 - 1.0 0.5 - 12.8 -
2003 - - 1.9 - 7.1 8.0 0 a - - 14.4 1.0
2004 2.3 - 3.4 1.0 3.0 6.6 1.7 0.0 6.4 20.8 -
Neomycin 2002 - 0 3.0 - 1.0 - 1.3 0.5 - 14.5 -
2003 - - 5.7 - 5.9 - 3.2a - - 13.7 1.0
2004 2.3 - 15.8 1.0 5.0 - 2.0 0.8 - 11.5 -
Streptomycin 2002 - 46 33.8 - 65.0 - - 20.8 - 70.9 -
2003 - - 43.9 - 67.0 49.0 - - - 72.3 13.0
2004 54.4 - 47.6 15.0 62.0 48.2 - 33.6 34.7 66.1 -
Sulphonamides 2002 - 73 23.2 - - - - 10.7 - 70.6 -
2003 - - 30.6 - - 51.0 - - - 77.5 9.0
2004 30.0 - 46.6 12.0 - - 52.7 12.0 15.9 73.2 -
Tetracycline 2002 - 80 25.9 - 89.0 - 57.7 7.4 - 91.0 -
2003 - - 30.2 - 81.2 66.0 69.7 a - - 93.0 12.0
2004 58.1 - 43.8 16.0 86.0 81.0 63.9 9.6 31.6 95.6 -
Trimethoprim 2002 - 68 6.1 - 61.0 - 43.0 4.8 - 69.2 -
2003 - - 13.6 - 48.0 - 43.9 a - - 76.5 4.0
2004 3.4 - - 8.0 44.0 - 5.7 4.0 1.0 66.7 -Page 8 of 10
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trends in resistance should be monitored carefully for A.
pleuropneumoniae. The results obtained should be made
available for veterinarians for an effective usage of these
drugs and to minimise the selection pressure for antimi-
crobial resistance.
Streptococcus suis
The resistance levels observed to trimethoprim – sul-
phonamide is comparable to previous reports from Den-
mark [13], France [14] and Japan [15]. The occurrence of
penicillin resistance reported from Denmark, Poland and
Portugal is surprising, since penicillin resistance in strep-
tococci is generally rare. Five isolates from Poland were re-
tested at the National Food Institute, Technical University
of Denmark. The MIC values found in Poland were con-
firmed (data not shown). The genetic mechanisms are not
finally elucidated but variations in the gene coding for the
penicillin binding proteins have been found in isolates
from both Denmark and Poland (unpublished results).
Thus, these results could indicate that penicillin resistance
is emerging in S. suis. This should be followed closely.
Escherichia coli
The occurrence of resistance in E. coli varied markedly
between antimicrobials and countries but seemed to be
very stable within countries over the three year period. We
recommend that the choice of empirical treatment for E.
coli infections based on the sparse data in this study needs
to be adapted according to the resistance situation in the
individual countries. In contrast to the general pattern of
susceptibility observed in A. pleuropneumoniae and S. suis,
resistance profiles of E. coli showed a marked geographic
variation. The susceptibility results in E. coli from other
studies support the results obtained in this study [16-19].
As a consequence only a limited number of antimicrobial
agents are useful for empirical treatment of infections in
pigs caused by this bacterium. With the emergence of
resistance to ciprofloxacin the options available for treat-
ment of intestinal infections are restricted to colistin
based on the selection of drugs included in this study.
However, due to the poor knowledge on resistance against
this antibiotic and the methodological difficulties in test-
ing susceptibility with disk diffusion methods, the actual
level of resistance against colistin is largely unknown
[20,21].
In general, the levels of resistance were lower in E. coli
from healthy pigs than in E. coli strains isolated from dis-
eased animals. This is partly due to a sampling bias of the
isolates from clinical cases which probably had a major
impact on the internal and external validity of results. In
fact, diagnostic specimens are mostly sent to the labora-
tory following severe illness, widespread disease or when
therapeutic failures occur. The level of resistance might
therefore be higher due to previous (unsuccessful) treat-
ment compared with isolates from healthy animals. In
such cases the laboratory receives a subset of pathogens
that often present resistance at a higher level than those
from the general population of pathogens, because the
animals may have already been treated with first-line anti-
microbials before sampling. However, the data clearly
show the occurrence of resistance in indicator bacteria
and highlight their potential role as an ordinary resistance
reservoir as a consequence of the use of antimicrobials in
livestock.
Conclusion
Occurrence of resistance to several antimicrobial agents
was observed for E. coli and in some cases also for S. suis.
This may reflect differences in the antimicrobial availabil-
ity, treatment procedures, and animal husbandry practices
between the different countries. In addition, the study
suggests that the choice of substances used for the treat-
ment of specific infections in animals has to be based on
knowledge of the local pattern of resistance. In the future,
the data from monitoring programs and resistance studies
should be taken into account for the usage of antimicro-
bials in veterinary medicine.
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